Jonsson Comprehensive Cancer Center

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.cancer.ucla.edu
Clinical Trials
Related News

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1
Withdrawn
Conditions
Lung Cancer
First Posted Date
2004-12-08
Last Posted Date
2012-10-04
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00098462

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2004-11-09
Last Posted Date
2013-06-26
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT00096057
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

🇺🇸

M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

🇺🇸

University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

First Posted Date
2004-11-09
Last Posted Date
2013-12-19
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00096239
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

First Posted Date
2004-10-08
Last Posted Date
2020-07-31
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
1
Registration Number
NCT00093704
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Not Applicable
Conditions
Graft Versus Host Disease
Leukemia
First Posted Date
2004-10-08
Last Posted Date
2013-11-06
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00093587
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

BMS-599626 in Treating Patients With Metastatic Solid Tumors

First Posted Date
2004-10-08
Last Posted Date
2012-10-04
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
9
Registration Number
NCT00093730
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer

Phase 1
Withdrawn
Conditions
Liver Cancer
First Posted Date
2004-10-08
Last Posted Date
2012-10-04
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00093548

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Drug: bortezomib + rituximab
First Posted Date
2004-10-08
Last Posted Date
2012-10-04
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
15
Registration Number
NCT00093769
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease

Phase 1
Conditions
Graft Versus Host Disease
First Posted Date
2004-09-16
Last Posted Date
2013-12-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00004194

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

First Posted Date
2004-09-09
Last Posted Date
2020-08-05
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT00091299
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy